DemeRx Inc. is developing ibogaine based treatments for opioid abuse. The company plans to advance ibogaine for opioid detoxification in medically-supervised inpatient settings as well as use Noribogaine as a low-dose adjunct therapy for patients in early recovery among other conditions.

In January 2020, the company announced that it received an investment in two joint ventures from ATAI Life Sciences AG, totaling $22 million to help advance its ibogaine-based treatment options.

Richard Serbin
Executive Chairman

Deborah Mash, Ph.D.
Founder & CEO

Michael Karukin, Ph.D.
Chief Operating Officer

Pascal Goldschmidt, MD, FACC, FAHA
Chief Medical Officer

John Thomas CPA
Chief Financial Officer